Geron Announces IMerge Phase 3 Presentations at ASH Highligh

Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS

Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , San Diego , California , America , American , Kristen Kelleher , Amer Methqal Zeidan , Optum Clinformatics , Aaron Feingold , Faye Feller , European Union , Geron Corporation Nasdaq , Linkedin , Exchange Commission , Large Us Health Insurance Claims Database , Corporate Communications , International Prognostic Scoring System , Yale Cancer Center , Drug Administration , Geron Corporation , American Society Of Hematology , American Society , Annual Meeting , Executive Vice President , Chief Medical , Associate Professor , Internal Medicine , Early Therapy Research , Yale School , Erythropoiesis Stimulating Agents , Mutational Status , Clinical Response , Lower Risk Myelodysplastic Syndromes , Patients With Heavily Transfused Non Del , High Transfusion Burden Treated With Imetelstat , Cancer Therapy Anemia , Myelodysplasia Scale , Imetelstat Treatment , Transfusion Independence , Lower Risk Myelodysplastic Syndrome , Better Survival , Population Level Analysis Based , Insurance Claims , Publications Section , North America , Middle East , Fast Track , Nobel Prize Winning , New Drug Application , United States Food , Prescription Drug User Fee Act , Private Securities Litigation Reform Act , Investor Relations ,